Methylene Blue and Depression: Research, Mechanism, and Critical Interactions

For dosing protocols used in research, see methylene blue dosage chart by body weight.

For the full drug interaction profile, see methylene blue drug interactions.

Nothing in this article constitutes medical advice. Methylene blue is sold by Perfect Blue Labs for research and laboratory purposes. Anyone with a history of mood disorders or on psychiatric medication must consult a qualified healthcare professional before any methylene blue exposure.

---

Looking for a Canadian source? See our complete guide on where to buy methylene blue in Canada — including what purity standards matter, how to evaluate suppliers, and what to avoid.

---

The MAO-A Inhibition Mechanism

Monoamine oxidase A (MAO-A) is an enzyme that breaks down monoamine neurotransmitters — including serotonin, norepinephrine, and dopamine — in the brain and gut. Inhibiting MAO-A allows these neurotransmitters to accumulate, which is the mechanism behind MAOI antidepressants (phenelzine, tranylcypromine, selegiline).

Methylene blue is a potent MAO-A inhibitor. A 2007 study by Ramsay, Dunford, and Gillman published in the British Journal of Pharmacology measured the inhibitory constant (Ki) for methylene blue's MAO-A inhibition at 27 ± 3 nM — a value indicating extremely tight binding that exceeds the potency of linezolid, a drug with established serotonin toxicity risk. At intravenous concentrations used in clinical settings, the study found that complete MAO-A inhibition occurs. Ramsay et al., Br J Pharmacol, 2007 → PMC2078225

This mechanism has two consequences that run in opposite directions:

1. It may contribute to antidepressant-like effects in individuals not on serotonergic medications (via monoamine accumulation)
2. It creates a serious interaction risk when combined with any medication that also increases serotonin activity

Clinical Research: What the Trials Found

Naylor, Smith & Connelly (1987) — Double-Blind Trial in Severe Depressive Illness

This double-blind, placebo-controlled clinical trial published in Biological Psychiatry examined 15 mg/day of oral methylene blue in patients with severe depressive illness over three weeks. The researchers found that improvement in patients receiving methylene blue was significantly greater than in those receiving placebo, and described the compound as functioning as a potent antidepressant at this dose level, warranting further clinical investigation. This is one of the earliest controlled human trials on methylene blue and mood. Naylor et al., Biol Psychiatry, 1987 → PubMed 3555627

Alda et al. (2017) — Randomized Crossover Trial in Bipolar Disorder

This double-blind, randomized crossover trial published in the British Journal of Psychiatry tested methylene blue as an adjunctive treatment in 37 patients with bipolar disorder. Participants received both 15 mg (effectively placebo-dose) and 195 mg of methylene blue in crossover fashion. Key findings:

• 195 mg significantly reduced depression symptoms on both the Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Rating Scale for Depression (HAM-D)
• Anxiety symptoms on the Hamilton Rating Scale for Anxiety (HAM-A) showed significant reduction
• Mania symptoms remained low and stable throughout (no manic induction)
• Medication was well-tolerated with mild, transient side effects

The authors concluded that adjunctive methylene blue improved residual depressive and anxiety symptoms in bipolar disorder. Alda et al., Br J Psychiatry, 2017 → PubMed 27284082

The Research Context: What These Studies Do and Don't Show

The clinical trials above are real and the findings are positive — but context matters:

• Both trials used methylene blue as an adjunctive treatment alongside standard psychiatric care, not as a standalone replacement
• The Alda 2017 trial specifically involved bipolar patients whose primary condition was already being managed, with MB addressing residual symptoms
• Neither trial constitutes approval or recommendation for methylene blue as a depression treatment
• The dose used in Naylor (15 mg/day) is substantially lower than doses used in cognitive research protocols

This body of research represents hypothesis-generating evidence — enough to motivate further investigation, but not sufficient to draw clinical conclusions. It describes what researchers have observed, not what patients should do.

The Serotonin Syndrome Risk: Why This Matters

Serotonin syndrome results from excess serotonergic activity in the central nervous system and can range from mild (shivering, diarrhea) to life-threatening (high fever, seizures, irregular heartbeat, unconsciousness). Cases of serotonin syndrome involving methylene blue have been documented in surgical patients who received IV methylene blue while on SSRIs.

The FDA has issued safety communications warning against the use of methylene blue in patients taking serotonergic medications. The risk is not theoretical — it has produced documented clinical cases, including fatalities.

The practical implication: anyone considering methylene blue who is currently taking or has recently discontinued an SSRI, SNRI, MAOI, tricyclic antidepressant, or other serotonin-affecting medication should not do so without direct physician oversight.

For the complete interaction profile, including a list of specific medications documented to interact, see methylene blue drug interactions.

The Mitochondrial Mechanism and Mood

Separate from the MAO inhibition pathway, methylene blue's mitochondrial mechanism has also been proposed as relevant to mood. Mitochondrial dysfunction has been identified as a feature of both depression and bipolar disorder in the research literature. Methylene blue's electron shuttle activity supports cellular energy production — a pathway that overlaps with the mitochondrial basis of mood disorders that has attracted research interest in recent years.

This dual mechanism (MAO inhibition + mitochondrial support) may explain why the clinical trials found effects at relatively low doses (15 mg) where MAO inhibition would be partial rather than complete.

---

---